Drug intelligence / Profile preview

GeneSoft

Development stage: Unknown
Lead developer: Uni-Bio Science Group
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

GeneSoft is an ophthalmic wound healing product developed by Uni-Bio Science Group. It is a derivative of recombinant human epidermal growth factor (rhEGF) that promotes corneal epithelium regeneration and enhances corneal wound healing. The drug has been commercially available in China since 2004 and is marketed through strategic alliances with companies like China Resources Zizhu Pharmaceutical and Shanghai Loymed Pharma Technology.

Brand names: GeneSoft
Other names: recombinant human epidermal growth factorrhEGFhEGFhuman epidermal growth factor

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on GeneSoft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneSoft.

Explore the full profile